5:12 PM
 | 
Mar 28, 2013
 |  BC Extra  |  Financial News

Biogen Idec gains on Tecfidera approval

Biogen Idec Inc. (NASDAQ:BIIB) was up $9.94 to $192.62 on Thursday on the heels of FDA's approval of Tecfidera dimethyl fumarate (formerly BG-12) to treat adults with relapsing forms of multiple sclerosis on Wednesday. The stock move...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >